RecruitingNCT06249269

Reversal of Atrial Substrate to Prevent Atrial Fibrillation Cohort Study


Sponsor

Ratika Parkash

Enrollment

198 participants

Start Date

May 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Atrial fibrillation (AF) is a major health problem, with a prevalence of 0.4-1% of the population. It results in high healthcare costs and significant morbidity, especially for patients with severe symptoms. The RASTA-AF randomized control trial (RCT) is designed to answer the following question: does vigorous treatment of AF with aggressive risk factor management plus catheter ablation reduce AF-related outcomes as compared to catheter ablation plus usual care in patients with symptomatic AF and risk factors that promote AF. This study is a multicenter, prospective cohort study that will enrol patients who decline participation in the RASTA-AF RCT but agree to be followed in a registry. The objective of RASTA-Cohort is to determine whether patients who decline participation in the RASTA-AF RCT have different clinical characteristics and quality of life than patients who accept participation in the study, and whether they suffer from worse AF-related outcomes than patients in the RCT.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • symptomatic AF (CCS-SAF ≥2),
  • paroxysmal or persistent atrial fibrillation despite rate control, desiring catheter ablation and either: i) BMI ≥ 30 or, ii) at least two of the following: BMI\>27, BP\>140/90 mmHg or history of hypertension, Diabetes, Heart failure (prior heart failure admission or LVEF\<40%), Age ≥ 65 years, Prior stroke/TIA, Current smoker, Excessive alcohol use {For women: 10 or more drinks/week, more than 2 drinks a day (most days). For men: 15 or more drinks/week, more than 3 drinks a day (most days)}, and iii) declined or were not approached for participation in the main study. Eligible patients must have received catheter ablation for AF during the same timeline of the RASTA-AF Mian Study (November 1st, 2019 to December 31st, 2025).

Exclusion Criteria9

  • permanent AF (AF lasting \> 3 years),
  • prior catheter ablation for AF
  • New York Heart Association Class IV heart failure
  • participation in a cardiac rehabilitation program within the last year,
  • currently performing exercise training \>150 minutes/week of moderate to vigorous physical activity,
  • unable to exercise,
  • unable to give informed consent,
  • other noncardiovascular medical condition making 1 year survival unlikely
  • less than 18 years of age

Locations(7)

Foothills Hospital

Calgary, Alberta, Canada

QEIIHSC

Halifax, Nova Scotia, Canada

London Health Sciences Centre

London, Ontario, Canada

University of Ottawa Heart Institute

Ottawa, Ontario, Canada

Sunnybrook Hospital

Toronto, Ontario, Canada

Montreal Heart Institute

Montreal, Quebec, Canada

Regina General Hospital

Regina, Saskatchewan, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06249269


Related Trials